	US 12,215,340 B2
	Recombinant arterivirus replicon systems and uses thereof
Kurt Iver Kamrud, Olathe, KS (US); Nathaniel Stephen Wang, San Diego, CA (US); Martina Felderman, La Jolla, CA (US); and Nancy C. Carrico, La Jolla, CA (US)
Assigned to Janssen Pharmaceuticals, Inc., Titusville, NJ (US)
Filed by Janssen Pharmaceuticals, Inc., Titusville, NJ (US)
Filed on Jan. 13, 2023, as Appl. No. 18/154,278.
Application 16/703,359 is a division of application No. 15/486,131, filed on Apr. 12, 2017, granted, now 10,538,786, issued on Jan. 21, 2020.
Application 18/154,278 is a continuation of application No. 16/703,359, filed on Dec. 4, 2019, granted, now 11,555,205.
Claims priority of provisional application 62/322,149, filed on Apr. 13, 2016.
Prior Publication US 2023/0227850 A1, Jul. 20, 2023
Int. Cl. C12N 15/86 (2006.01); A61K 48/00 (2006.01); C07K 14/005 (2006.01); C07K 16/32 (2006.01); C12P 21/00 (2006.01)

CPC C12N 15/86 (2013.01) [A61K 48/005 (2013.01); C07K 14/005 (2013.01); C07K 16/32 (2013.01); C12P 21/00 (2013.01); C07K 2317/14 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2319/00 (2013.01); C12N 2760/16122 (2013.01); C12N 2760/18522 (2013.01); C12N 2770/10021 (2013.01); C12N 2770/10043 (2013.01)]

1 Claim

1. A nucleic acid molecule comprising a nucleotide sequence encoding a modified equine arterivirus genome or replicon RNA, wherein the modified equine arterivirus genome or replicon RNA comprises a gene encoding a polypeptide of interest and a nucleotide sequence encoding a modified Equine arteritis virus (EAV) genome or replicon RNA, wherein the modified EAV genome or replicon RNA comprises a sequence fragment exhibiting at least 80% sequence identity to the sequence encoding open reading frame ORF7 of the wild-type sequence of EAV, and wherein the modified genome or replicon RNA is devoid of the sequence encoding ORF2a.